Literature DB >> 19209124

Andrological characterization of the patient with diabetes mellitus.

S La Vignera1, A E Calogero, R Condorelli, F Lanzafame, B Giammusso, E Vicari.   

Abstract

AIM: In the management of the chronic complications caused by diabetes mellitus, an important role is played to andrological problematics, which require a specialistic evaluation combined in order to concretely contribute to the improvement of quality of life of such patients. The erectile disfunction in the diabetic patient notoriously correlates with the main cardiometabolics risk factors, and recently it has been pointed out how after chronic use of inhibitors of the phospodiesterase-enzyme-5 (PDE5-I) it is possible to improve the vascular response profile, evaluated through ecolor doppler (ECD) penile dynamic. The incidence of the vascular extra-genital pathology in the patients with ED of organic arterial type has also been observed, underlining in particular the correlation with a low value of the systolic peak at penile level. Little attention has been paid to other andrologic pathologies that preliminary clinic evidences or less followed research points have individuated as real emerging problems; among them there are: 1) the hypogonadism in adult age (late onset hypogonadism); 2) the lower urinary tract symptoms (LUTS) correlated to the condition of prostatic hypertrophy; 3) the infections of the male genito-urinary tract with different characterization for imaging respect to the not diabetic population; 4) different sexual disorders; 5) implications over the male reproductive sphere.
METHODS: Retrospective analysis of the clinic, laboratory (spermatic, microbiologic and hormonal), ultrasonography integrated data, led on a diabetic population examined during the last 3 years; finalized at the estimation of the distribution of the andrological pathology characterizing such population, with the comparison of the data on the basis of years of duration disease, grade of glicometabolic compensation and levels of total testosterone.
RESULTS: ED was present in 16.36% of the examined population; 50% showed vascular arterial form; hypogonadism was present in 10% of the population. A very high prevalence of subfertility was observed 51.82%. The ultrasonographic characterization of the didimo-epididimary and prostatic-vesicular regions showed reduced testicular volume the 16.36% of cases, increase of the prostatic glandular volume in 45.45% of cases, altered thickness of the seminal vesicles in the 24.45% of cases. The microbiologic characterization evidences the contemporary positivity of the 3 prechosen indicators (spermiocolture, urinocolture, leukocytospermia) in 34.55% of patients.
CONCLUSIONS: The study has contributed to enrich the data relative to the heterogeneity of the clinic-andrological presentation of the diabetic patient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19209124

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  18 in total

Review 1.  Antiretroviral Therapy and Alcohol Interactions: X-raying Testicular and Seminal Parameters Under the HAART Era.

Authors:  Oluwatosin O Ogedengbe; Edwin C S Naidu; Onyemaechi O Azu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-04       Impact factor: 2.441

Review 2.  Testosterone supplementation and body composition: results from a meta-analysis of observational studies.

Authors:  G Corona; V A Giagulli; E Maseroli; L Vignozzi; A Aversa; M Zitzmann; F Saad; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-05-30       Impact factor: 4.256

Review 3.  Male sexual dysfunction and infertility associated with neurological disorders.

Authors:  Mikkel Fode; Sheila Krogh-Jespersen; Nancy L Brackett; Dana A Ohl; Charles M Lynne; Jens Sønksen
Journal:  Asian J Androl       Date:  2011-12-05       Impact factor: 3.285

4.  Expression of cyclooxygenase-1 (COX-1) and COX-2 in human male gametes from normal patients, and those with varicocele and diabetes: a potential molecular marker for diagnosing male infertility disorders.

Authors:  I Perrotta; M Santoro; C Guido; P Avena; S Tripepi; F De Amicis; M C Gervasi; S Aquila
Journal:  J Anat       Date:  2012-07-02       Impact factor: 2.610

5.  Momordica cymbalaria improves reproductive parameters in alloxan-induced male diabetic rats.

Authors:  Abbirami Elangovan; Siva Durairaj; Abinaya Subramanian; Sooraj Ramakrishnan; Dinesh Kumar Lakshmanan; Guna Ravichandran; Sivasudha Thilagar
Journal:  3 Biotech       Date:  2021-01-15       Impact factor: 2.406

6.  Antioxidative effects of cerium dioxide nanoparticles ameliorate age-related male infertility: optimistic results in rats and the review of clinical clues for integrative concept of men health and fertility.

Authors:  Nazarii M Kobyliak; Tetyana M Falalyeyeva; Olena G Kuryk; Tetyana V Beregova; Petro M Bodnar; Nadiya M Zholobak; Oleksandr B Shcherbakov; Rostyslav V Bubnov; Mykola Ya Spivak
Journal:  EPMA J       Date:  2015-06-10       Impact factor: 6.543

Review 7.  Fertility treatment in spinal cord injury and other neurologic disease.

Authors:  Vera Trofimenko; James M Hotaling
Journal:  Transl Androl Urol       Date:  2016-02

8.  High regenerative capacity of the liver and irreversible injury of male reproductive system in carbon tetrachloride-induced liver fibrosis rat model.

Authors:  Rostyslav V Bubnov; Maria V Drahulian; Polina V Buchek; Tamara P Gulko
Journal:  EPMA J       Date:  2017-10-11       Impact factor: 6.543

9.  Effect of Alpinia officinarum extract on reproductive damages in streptozotocin induced diabetic male rats.

Authors:  Hamid Heidari; Maasoume Abdollahi; Sima Khani; Fatemeh Nojavan; Samira Khani
Journal:  J Diabetes Metab Disord       Date:  2021-01-22

10.  Ameliorative Effect of Zinc Oxide Nanoparticles on Antioxidants and Sperm Characteristics in Streptozotocin-Induced Diabetic Rat Testes.

Authors:  Mohamed Afifi; Omar A Almaghrabi; Naif Mohammed Kadasa
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.